Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effectiveness (prevention of
thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to
background antiplatelet therapy in patients who develop new-onset post-operative atrial
fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.
All patients with a qualifying POAF event, who decline randomization, will be offered the
option of enrollment in a parallel registry that captures their baseline risk profile and
their treatment strategy in terms of anticoagulants or antiplatelets received. These patients
will also be asked to fill out a brief decliner survey.
Phase:
Phase 4
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) Vanderbilt University Medical Center